Skip to content
Subscriber Only

Jack Ma-Backed Biotech Firm Brii Considers Hong Kong IPO

  • Brii could seek a listing as early as in the first quarter
  • Company is also looking to raise $100 million in pre-IPO round
Russia Registers Gamaleya Covid-19 Vaccine
Photographer: Andrey Rudakov/Bloomberg

Brii Biosciences, which focuses on treatments for diseases such as Covid-19 and HIV, is considering an initial public offering in Hong Kong as soon as the first quarter of next year, according to people familiar with the matter.

The biotech firm is working with investment banks on the potential listing, which could raise about $200 million to $400 million, the people said. Brii is also seeking about $100 million via a pre-IPO funding round from private investors, said the people, asking not to be identified because the matter is private.